1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNIH IMPROVE Initiative: Maternal Health Technology & Digital Care SBIR Funding Opportunity is sponsored by National Institutes of Health (NIH). This SBIR funding opportunity under the NIH IMPROVE Initiative encourages supplemental research proposals that enhance and expand the Maternal Health Research Centers of Excellence and Hubs.
Get alerted about grants like this
Save a search for “National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NIH IMPROVE Initiative: Maternal Health Technology & Digital Care SBIR Funding Opportunity — BW&CO NIH Highlighted Topic: Enhancing the IMPROVE-funded Maternal Health Centers of Excellence Below is a brief summary. Please check the full solicitation before applying (link in resources section).
The National Institutes of Health (NIH) is encouraging supplemental research proposals that enhance and expand the IMPROVE-funded Maternal Health Research Centers of Excellence and Hubs. This highlighted topic supports projects designed to accelerate research and innovation aimed at reducing maternal morbidity and mortality, particularly in underserved regions and populations with disproportionately poor maternal health outcomes.
The initiative is part of the NIH Implementing a Maternal Health and Pregnancy Outcomes Vision for Everyone (IMPROVE) Initiative and seeks to strengthen ongoing maternal health research through expanded geographic reach, collaborative partnerships, and integration of emerging maternal health technologies.
NIH is especially interested in projects that expand research into maternity care deserts and regions with high rates of maternal mortality and severe maternal morbidity.
Companies developing maternal health technologies, remote patient monitoring systems, digital health platforms, AI-enabled maternal risk prediction tools, telehealth infrastructure, wearable devices, pregnancy monitoring technologies, clinical analytics systems, or healthcare coordination platforms may be strong candidates for funding.
Areas of interest include maternal mortality prevention, pregnancy-related complication monitoring, rural and underserved healthcare delivery, collaborative maternal health research networks, digital diagnostics, remote monitoring, and integration of technologies developed through the RADx maternal health challenge.
NIH is also encouraging scalable technologies and interventions that improve maternal outcomes, access to care, and longitudinal pregnancy health monitoring. Funding is available through the NIH SBIR/STTR Program and related NIH supplemental funding mechanisms, with opportunities for both translational research and commercialization support depending on project scope and alignment with existing IMPROVE-funded Centers and Hubs.
This highlighted topic is supported primarily by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which is seeking transformative innovations that improve maternal healthcare access, clinical outcomes, and implementation of advanced maternal health technologies. How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for? Funding may support the research, development, validation, implementation, and commercialization of maternal health technologies, remote monitoring systems, clinical analytics platforms, and healthcare delivery solutions designed to reduce maternal morbidity and mortality.
Eligible activities may include: Remote maternal monitoring and wearable pregnancy technologies AI and machine learning platforms for maternal risk prediction Telehealth systems for prenatal and postpartum care Digital diagnostics and point-of-care maternal health technologies Healthcare coordination and maternal care navigation platforms Expansion of maternal health programs into maternity care deserts Pregnancy complication monitoring and early warning systems Clinical decision support systems for maternal healthcare providers Integration of RADx maternal health technologies into care delivery Population health analytics and maternal outcomes tracking systems Community-based maternal health intervention technologies Longitudinal pregnancy and postpartum monitoring platforms Rural maternal healthcare access and infrastructure technologies Collaborative maternal health data-sharing and interoperability systems Equity-focused maternal health implementation and outreach platforms Prototype development, implementation studies, and translational research Commercialization planning, regulatory preparation, and scale-up activities Funding may also support personnel, software engineering, cloud infrastructure, AI model development, wearable integration, clinical validation studies, telehealth deployment, healthcare systems integration, community engagement, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable maternal health solution aligned with NIH priorities.
Are there any additional benefits I would receive? Beyond the formal funding award, awardees gain several strategic advantages: Government Validation and Credibility: Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.
Enhanced Visibility and Market Recognition: Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities. Access to the Federal Innovation Ecosystem: Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.
Stronger Commercial and Exit Potential: By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment. What is the timeline to apply and when would I receive funding? Applications are accepted each year on January 5th, April 5th, and September 5th.
Funding is received approximately 9 months after submission. Where does this funding come from? Funding comes from the U.S. Department of Health and Human Services , with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.
2% for SBIR, 0. 45% for STTR) to support small business innovation. Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that: Are organized for profit with a U.S. place of business. Have ≤ 500 employees including affiliates. Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win? Projects that demonstrate: A clear unmet medical or public-health need , Strong scientific rationale and feasibility , High commercialization potential , supported by a realistic market and regulatory strategy, and Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption. Are there any restrictions I should know about? Companies must complete multiple federal registrations ( SAM.
gov , Grants. gov , eRA Commons, SBA Company Registry) before applying. Foreign entities are not eligible .
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation. How long will it take me to prepare an application?
For a first-time applicant , preparing a competitive submission will likely take 120–200 hours in total.
Our team specializes in complex federal R&D proposals and can: Triple your likelihood of success through proven strategy and insider-aligned proposal development Reduce your time spent on the proposal by 50–80% , letting your team focus on technology and operations Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth. Review solicitation here.
Biotech Medtech Healthtech NIH Highlighted Topic: Advancing Mechanism-driven Translational Research of Beneficial and Detrimental Effect of Psilocybin on Cancer and Other Health Conditions NIH Highlighted Topic: Accelerating Hidradenitis Suppurativa Research
According to the current listing, eligibility includes: U. S. small business concerns (SBCs) that are organized for profit with a U. S. place of business and have ≤ 500 employees including affiliates. Confirm the full requirements in the official notice before applying.
NIH IMPROVE Initiative: Maternal Health Technology & Digital Care SBIR Funding Opportunity is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NIH NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) is a grant from the National Institutes of Health (NIH) / National Cancer Institute (NCI) that funds early-stage postdoctoral researchers in cancer-related fields to transition to independent research careers. The award provides a mentored phase (K99) followed by an independent phase (R00), supporting investigators who do not require an extended period of supervised training beyond their doctoral degrees. Eligible applicants must hold a research or clinical doctoral degree and be postdoctoral fellows who have not yet established independent research careers. The March 11, 2026 due date applies; award amounts vary by project.
NIH R25 Summer Research Education Experience Program is a grant from the National Institutes of Health (NIH) that funds universities and institutions of higher education to provide summer research experiences in environmental health sciences to high school students, college undergraduates, and science teachers. Administered through the National Institute of Environmental Health Sciences (NIEHS), the program aims to attract young people to scientific careers and help teachers communicate about the scientific process more effectively. Eligible applicants are U.S. institutions eligible for NIH grants. The application deadline was March 17, 2026.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
The April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read articleNIH's accelerating use of multiyear-funded grants — 601 awards worth $402 million in the first half of FY26, against just 146 awards worth $75 million in the same window of FY24 — has produced a fiscal contraction at research universities that has begun cascading into PhD admissions. AAU member institutions are admitting smaller graduate cohorts than they did in 2024 or 2025, with downstream consequences for the biomedical workforce, lab continuity, and the foreign-student pipeline through 2030. Why the contraction is structural rather than cyclical, and what universities, PIs, and prospective trainees should be doing in the second half of 2026.
Read articleNIH has no active SBIR or STTR omnibus solicitations for the first time in a decade. The FY26 reset reposts the omnibus series on June 1 with a September 8 deadline and a quietly historic change — Direct-to-Phase II STTR awards. Here is the strategy.
Read article